Buscar
Rigel Pharmaceuticals Inc
RIGLAñadir a la lista de seguimiento
36.815USD
-1.245-3.27%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
667.97MCap. mercado
1.82P/E TTM
Más Datos de Rigel Pharmaceuticals Inc Compañía
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Información de Rigel Pharmaceuticals Inc
Símbolo de cotizaciónRIGL
Nombre de la empresaRigel Pharmaceuticals Inc
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoRodriguez (Raul R)
Número de empleados162
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 29
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónRIGL
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoRodriguez (Raul R)
Ejecutivos de Rigel Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
279.59K
-0.87%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
78.79K
+3.11%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.00K
-1.41%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.00K
-2.50%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
18.47K
+31.13%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
18.25K
+31.51%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
10.13K
-24.69%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
279.59K
-0.87%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
78.79K
+3.11%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.00K
-1.41%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.00K
-2.50%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
18.47K
+31.13%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
18.25K
+31.51%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Rigel Pharmaceuticals Inc?
Los cinco principales accionistas de Rigel Pharmaceuticals Inc son: Mr. Raul R. Rodriguez
¿Cuántas instituciones poseen acciones de Rigel Pharmaceuticals Inc (RIGL)?
A fecha de 2026Q1, 365 instituciones poseen acciones de Rigel Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 17.75M, lo que representa el 95.95% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 784716.00.